Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes.

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...

The prevalence of overweight and obesity has reached pandemic proportions, affecting more than 1 billion people worldwide; it ...

Zydus Lifesciences Ltd and Torrent Pharmaceuticals Ltd are preparing to enter the fast-growing market for Semaglutide — a ...

OpenAI CEO Sam Altman said that he tried semaglutide "before it was cool," and his busy life has made it harder to focus on his health.

Scientists say they’ve come up with a way for the body to produce its own store of glucagon-like peptide-1 (GLP-1). GLP-1 is ...

New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

Oral semaglutide improved glycemic parameters and cardiovascular risk factors for adults with overweight or obesity, with ...

Camurus (NASDAQ STO: CAMX) today announced positive topline results from a randomized, active-controlled Phase 1b study evaluating CAM2056, the company's monthly FluidCrystal® semaglutide formulation, ...

Preliminary research suggests that NG101, a drug from Neurogastrx, may lower the risk of nausea and vomiting in people taking ...

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...